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The World Health Organization currently recommends artemisinin (along with a partner
drug) as the global frontline treatment for Plasmodium falciparum malaria. Artemisinin resis-
tant P. falciparum are now found throughout the greater Mekong subregion of South East
Asia. Several polymorphisms in the parasite’s kelch gene have been demonstrated to confer
artemisinin resistance. While genotypes within the greater Mekong subregion are thor-
oughly examined in the literature, P. falciparum populations within several areas that do not
(yet) have endemic resistance are underrepresented.
Results
This investigation characterised the Pfkelch13 propeller domains from 153 blood samples of
140 imported cases of P. falciparum malaria in New South Wales from 2010 to 2016. A low
level of propeller domain diversity was observed, including the C580Y coding mutation most
strongly associated with artemisinin resistance in South East Asia. The resistance genotype
was found in a sample originating in Papua New Guinea, where this mutation, or artemisinin
treatment failure, have not been previously reported. Sequencing a panel of geographically
informative polymorphisms within the organellar genomes identified the C580Y parasite as
having Oceanic origins. Patient data analysis revealed that New South Wales, Australia,
P. falciparum malaria cases often originated from regions with limited drug resistance
screening.
Conclusions
The C580Y finding from outside of the greater Mekong subregion supports the consensus
to upscale molecular surveillance of artemisinin resistance outside of South East Asia. The
genetic screening results identify a risk of importing resistant falciparum malaria to Australia,
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supporting an ongoing surveillance protocol to pre-empt treatment failure and contribute to
global data gathering.
Introduction
The global frontline treatment for Plasmodium falciparum malaria is Artemisinin Combina-
tion Therapy (ACT) [1]. In the absence of an alternative frontline therapy, it is of utmost
importance ACT efficacy is preserved. Artemisinin treatment failure was first observed on the
Thai-Cambodian border and has since spread throughout the greater Mekong subregion of
South East Asia [2]. Artemisinin resistance is characterised by a parasite clearance half-life of
>5hrs, although ACT resistance needs to be considered together with sensitivity to the ACT
partner drug [3]. Landmark studies conducted in 2008 by Noedl et al. and 2009 by Dondorp
et al. first reported artemisinin resistance [4, 5]. More recently, resistance is described regard-
ing known molecular markers. Several Single Nucleotide Polymorphisms (SNPs) within the
propeller domain of the parasite’s Pfkelch13 gene have been associated with the resistant phe-
notype [6]. These Pfkelch13 SNPs were demonstrated to decrease artemisinin sensitivity when
inserted into Cambodian isolates [7]. The function/s of the Pfkelch13 protein is unclear,
though it appears to play a role in triggering the unfolded protein response following protein
damage [8]. Sustained alterations of the Pfkelch13 protein are not anticipated, unless the
changes serve to evade or counteract the mechanisms of action of artemisinin (that is, disrupt-
ing haem detoxification in the digestive vacuole, and producing oxidative damage by protein/
haem alkylation) [9].
The Pfkelch13 coding mutation most strongly associated with artemisinin resistance
(C580Y) is found throughout South East Asia and is approaching fixation in western Cambo-
dia [6, 10]. Resistance mutations have emerged independently in several South East Asian pop-
ulations [11]. Nonsynonymous Pfkelch13 mutations outside of South East Asia are rare. In
Africa the most commonly observed mutation is the A578S (reported at 3.8%, KARMA study
2014). This mutation has not been shown to delay parasite clearance and did not confer arte-
misinin resistance when inserted into a Dd2 parasite line collected from South East Asia [12].
South East Asia has historically acted as a cradle for antimalarial resistance. Resistance to
drugs such as chloroquine and sulfadoxine-pyrimethamine initially emerged in South East
Asia, then later disseminated to other endemic areas [13]. There is a significant risk that the
artemisinin resistant phenotypes within the greater Mekong subregion may similarly spread to
other endemic regions.
Molecular surveillance is an important tool for resistance containment. Monitoring clinical
outcomes alone may not facilitate the expedient identification and elimination of resistance
phenotypes needed to forestall wide-spread resistance. Molecular surveillance is especially vital
in sub Saharan Africa, where the majority of disease burden falls, and where immunity is likely
to mask treatment failure [14].
Molecular surveillance capacity has yet to be achieved for several endemic regions. Molecu-
lar data is typically collected by independent studies, and not ongoing routine surveillance.
Here travellers represent a convenient resource to include neglected regions in monitoring of
drug resistance [15]. Associated patient data allows genotyping results to be reconciled with
epidemiologically important data such as prophylaxis use and specific locations visited (for
purposes of reporting novel resistance genotype emergence).
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This study aimed to create a profile of epidemiologically relevant information from analys-
ing individual patient data, and to characterise the Pfkelch13 propeller domains of P. falcipa-
rum found in whole blood samples (n = 153) archived at the New South Wales (NSW) malaria
reference lab from travelers returning with P. falciparum malaria over the period 2010 to 2016.
Materials and methods
Samples
The study used 153 P. falciparum positive whole blood samples (diagnosed by microscopy),
archived 2010 to 2016 at the NSW parasitology reference laboratory at Westmead Hospital,
Sydney, NSW. A single blood sample was available for 127 cases, and 13 cases had stored both
a blood sample from before and after commencement of treatment. Available patient data had
been previously collected by patient interview and recorded within clinician’s notes. Accession
numbers were assigned to samples, and epidemiologically relevant decoded patient data were
recorded (see Table A in S1 File). As an experimental control, DNA from lab reference strain
3D7 P. falciparum kindly provided by Dr Jutta Marfurt (Menzies School of Health Research,
NT, Australia) was included. Samples were stored at -20˚C when not in use. This research was
conducted under the ethics approval number LNR/16/WMEAD/62 granted by the Westmead
Research Governance Office, Western Sydney Local Health District, NSW, Australia.
DNA extraction
Genomic DNA was extracted from whole blood samples using a GenElute™ Mammalian
Genomic DNA Miniprep Kit (Sigma-Aldrich, USA) as per manufacturer’s directions. DNA
quality was confirmed by subjecting DNA to gel electrophoresis. DNA concentrations were
measured by spectrophotometric analysis using a Nanodrop1 Spectrophotometer ND-1000 at
260nm and 280nm.
Pfkelch13
Amplification of the propeller region of the Pfkelch13 gene was adapted from Kamau et al.
2015 [16]. GeneDB accession number PF3D7_1343700 (http://www.plasmodb.org; accessed 6
July 2016) was used as a reference sequence in these studies, as this curated reference strain is
artemisinin susceptible, and contains no Pfkelch13 mutations. The primers used were outer
primers (Forward: 50 GCCTTGTTGAAAGAAGCAGAA 30, Reverse: 50 CGCCATTT
TCTCCTCCTGTA 30) capturing codon 427–691 of the Pfkelch13 propeller gene, semi-nested
primers (Forward: 50 GCCTTGTTGAAAGAAGCAGAA 30, Reverse: 50 GTG GCAGC
TCCAAAATTCAT 30) capturing codon 427–676.
The PCR reaction conditions were: Primary Master Mix (MM1) of 25μl total reaction vol-
ume containing 2.5μl 10 x PCR buffer (100 mM Tris-HCL, pH 8.3, 500 mM KCl, 15 mM
MgCl2, 0.01% w/v gelatine), 0.75 μl 50mM MgCl2, 2μl 2mM dNTP mix (dinucleotide triphos-
phates, containing 3 mM dATP and dTTP, 1 mM dCTP and dGTP,), 0.625μl outer forward
primer (10μM), 0.625μl outer reverse primer (10μM), 0.4μl BioTAQ DNA polymerase (5U/μl)
plus 11.1 μl of sterile water. Template DNA = 7μl/reaction.
The outer PCR product (5μl) was added to Secondary Master Mix (MM2) of the same com-
ponent concentrations of MM1 except that different reverse primer (semi-nested reverse
primer) was used. The reaction volume was made up to 50 μl for the semi-nested PCR.
All reactions were accompanied by a negative control containing sterile water, and other-
wise identical reaction conditions.
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Amplification was carried out in a Sensoquest Labcycler thermal cycler, with cycling condi-
tions outer round as follows: initial denaturation at 95˚C for 15 minutes, followed by 35 cycles
of denaturation at 95˚C for 1 minute, annealing at 59˚C for 1 minute, and extension at 72˚C
for 2 minutes, with a final extension at 72˚C for 10 minutes; semi-nested round: initial dena-
turation at 95˚C for 15 minutes, followed by 40 cycles of denaturation at 95˚C for 30 seconds,
annealing at 60˚C for 1 minute, and extension at 72˚C for 1 minutes, with a final extension at
72˚C for 10 minutes.
Geotyping
Primers were designed using Primer3 (http://simgene.com/Primer3) to amplify 15 regions
within the mitochondrial and apicoplast P. falciparum genomes. The 15 amplicons were cho-
sen to capture 23 neutrally inherited SNPs which create a highly predictive geographically
informative barcode [17]. Primers and PCR conditions can be found in Table B and Fig A in
S1 File. Geotyping amplicon sequences were aligned to P. falciparum 3D7 reference organellar
genome sequences Pf_M76611 (mitochondrial) and PfC10_API_IRAB (apicoplast) (http://
www.plasmodb.org; accessed May 2nd, 2017).
SNP analysis
Pfkelch13 and geotyping PCR products were sent to Macrogen (South Korea), for bidirectional
sequencing. Sequence data were validated by BLASTN and BLASTX searches (https://blast.
ncbi.nlm.nih.gov/Blast.cgi). Sequences were cropped of low quality ends using 4Peaks (http://
nucleobytes.com/4peaks/). Trusted regions of reverse sequences were processed using Rever-
seComplement (http://www.bioinformatics.org/sms/rev_comp.html). All generated sequences
per sample were combined to form a sample consensus sequence (contig) using 3cap (http://
doua.prabi.fr/software/cap3). Patient contigs were then aligned (using the MEGA7 integrated
MUSCLE multiple sequence alignment program) to the reference sequence to identify poly-
morphisms. Pfkelch13 variants were compared to reported resistance-associated mutations
[18]. Geotyping SNP locations were compared to distinct haplotypes of the geographically
informative barcode (see Fig A in S1 File) [17].
Accession numbers
Sequences for the Pfkelch13 propeller domain determined from each isolate can be found in
GenBank; accession numbers for patients 1–153 are MF076071—MF076223 respectively.
Results
Kelch propeller characterization
146 samples aligned identically to the reference Pfkelch13 gene ID PF3D7_1343700, including
all duplicate samples (collected before and after treatment). Variance from the reference
Pfkelch13 gene was found in 6 samples originating from Africa (non-coding SNPs) as well as
in one sample from Papua New Guinea (coding SNP) as detailed in Table 1.
Resistance-associated genotype
The protein translations of variant sequences were compared to the known resistance-associ-
ated Pfkelch13 alleles. This revealed the nucleotide polymorphism found in isolate BDB5,
extracted from a traveler returning from Papua New Guinea, resulted in the C580Y artemisi-
nin resistance mutation.
Imported artemsinin resistant P. falciparum
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Geotyping
The barcode generated for the mutant Papua New Guinea sample (isolate BDB5) aligned to a
haplotype unique to Oceania, as shown below in Fig 1.
Patient profile
Most specimens originated from Africa (n = 141). A considerable proportion of the African
cohort travelled to Australia from Nigeria (n = 28) or Sudan (n = 26). Additional African
countries included Kenya (n = 15), Ghana (n = 13), Sierra Leone (n = 5), and the Gambia
(n = 5). African countries of origin were grouped largely to the west and east geographical
regions of the continent. Travellers included refugees as well as immigrants having visited
rural areas to meet family obligations (Table A in S1 File).
Six patients had travelled to Papua New Guinea, two patients from both Indonesia and
India, one patient returned from Peru, and one patient returned from Thailand.
The study population was composed of 121 males and 32 females, with a mean age of
37.54±10, ranging from 6 months to 79 years old (at time of infection). The mean parasitaemia
was 1.55% erythrocytes infected, with less than 24% of samples <0.01%. Few patients (where
reported) had used chemoprophylaxis (doxycycline, artemether-lumefantrine, or mefloquine).
Instances of co-morbidity were low (reported in less than 5% of cases, most commonly dengue
fever).
Discussion
Considering the significant health threat artemisinin resistance represents, there is a consensus
to upscale surveillance of molecular markers outside of South East Asia [19]. The Pfkelch13
molecular surveillance studies which have been conducted in Africa thus far do not include
Zimbabwe or Sudan (origins of parasites examined in this study) [20]. Recently, ongoing resis-
tance surveillance has begun in 15 African locations (reporting the Plasmodium Diversity Net-
work of Africa) [18]; in this study, parasites were screened from origins that are not yet
included in this network (Nigeria, Sudan, Sierra Leone, Zambia, Malawi, Uganda, Mozam-
bique, Zimbabwe, Benin, and Togo).
The age and sex distribution of the cohort differed from that of studies conducted within
endemic regions, as is expected with a large proportion of non-immune travelers [21]. The
substantial gender bias observed in this study is unlikely to denote a controverting factor,
Table 1. Mutations found in Pfkelch13 propeller domain. SNPs found within Pfkelch13 propeller consensus sequences (n = 153) as compared to reference 3D7 P. falcip-
arum sequence.
Isolate Codon Nucleotide Change? Amino Acid Change? Parasite Origin
BDA57 469 CAA -> CAG Glutamine (synonymous) Nigeria
BDA64 469 CAA -> CAG Glutamine (synonymous) Africa
BDA85 474 ACA -> ACT Threonine (synonymous) Ghana (Dakwa)
BDB3 477 TCT -> TCG Serine (synonymous) Zambia
BDA83 491 TTC -> TTT Phenylalanine (synonymous) West Kenya
BDB5 580 TGT -> TAT Cysteine -> Tyrosine Papua New Guinea
BDA60 621 GCT -> GCA Alanine (Synonymous) Nigeria
Notes:
The non-synonymous T474I SNP at this codon site has previously been associated with artemisinin resistance [7].
 The C580Y kelch mutation is the molecular marker most strongly associated with artemisinin resistance [8].
https://doi.org/10.1371/journal.pone.0197369.t001
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Fig 1. Geographically informative barcode of P. falciparum organellar genome SNPs. The C580Y Papua New Guinea (BDB5) sample sequence
results for the 23 predictive geotyping SNP loci are compared to the geographically informative haplotype barcodes previously defined (predictive
accuracy 92.1%) [17]. SAM (South America); WAF: West Africa; EAF: East Africa; SEA: South East Asia, OCE: Oceania. Haplotype 10 represents
the 3D7 reference P. falciparum. SNP loci api2772 additionally occurs at nucleotide position api31461due to an inverted repeat within the
apicoplast genome.
https://doi.org/10.1371/journal.pone.0197369.g001
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given men and women historically present differing travel-related morbidity profiles [22]. The
current Australian treatment guidelines for uncomplicated P. falciparum malaria recommend
Artemether-lumefantrine (Riamet1, Coartem1) as the frontline treatment, or as a second
choice Atovaquone-proguanil (Malarone1) (in cases where atovaquone-proguanil has not
been taken as prophylaxis), and as a last choice alternative Quinine with clindamycin. All
patients within this study, including the patient from whom the C580Y sample (BDB5) was
collected, responded to treatment with no evidence of delayed parasite clearance.
The low level of Pfkelch13 propeller domain nucleotide diversity found in this study con-
forms to expectations [23]. No coding mutations were observed in African parasites, which is
consistent with most Pfkelch13 investigations of natural P. falciparum populations [16, 18, 24].
This is expected in the absence of widespread artemisinin use, as there is presumably a purify-
ing selection for the unaltered allele in the absence of a selective drug pressure [25].
The C580Y isolate (BDB5) originated from Papua New Guinea, where there is no report of
delayed parasite clearance with artemisinins, and there has been no previous observation of
this or any other resistance-associated Pfkelch13 mutations to our knowledge. Resistance
genotypes have additionally not been reported in countries adjacent to both Papua New
Guinea and the greater Mekong subregion, where resistant parasites would likely be observed
before Papua New Guinea in the instance of typical dissemination [26]. Clinical investigation
by the Tracking Resistance to Artemisinins Collaboration (TRAC) and molecular investigation
conducted by the MalariaGEN Plasmodium falciparum project confides the perimeter of arte-
misinin resistance to the greater Mekong subregion [16, 4].
There is a historical precedence both for native Papua New Guinea P. falciparum to give
rise to de novo resistance, as well as to acquire resistance from South East Asia via human
migration and the three anopheles vector species common to both regions [27]. Resistance to
pyrimethamine and chloroquine both emerged within Papua New Guinea independently, and
individually migrated from South East Asian locations [28].
The geotyping result identified the Papua New Guinea sample as haplotype #31 (Fig 1), a
haplotype unique to Oceania [17]. This result predicts that the sample is indigenous to Ocea-
nia, rather than having evolutionary origins within the artemisinin resistance perimeter. It is
possible the indigenous Papua New Guinea parasite generated the coding mutation de novo, or
potentially recombined with a migrating lineage from the greater Mekong subregion. The
patient did not experience treatment failure with ACT. It cannot be assumed that the C580Y
Pfkelch13 mutation alone conferred resistance in this case. The capacity for natural P. falcipa-
rum populations, including those of the pacific region, to generate artemisinin resistance is
unclear. Additional molecular markers may be necessary to discern artemisinin resistance out-
side South East Asia [29].
Resistance to conventional antimalarial drugs has previously spread though Papua New
Guinea in a hard selective sweep; that is, a single allele spreading through a population as
opposed to multiple adaptive alleles [30]. Genome Wide Association Studies conducted in
2015 found four background alleles (ferredoxin, apicoplast ribosomal protein S10, multidrug
resistance protein 2, and chloroquine resistance transporter) strongly associated with kelch-
mediated artemisinin resistance. These alleles are consistently present within founder popula-
tions in South East Asia [31]. These may be markers of a permissive genome more likely to
generate resistance, elements of a multi-loci gene network that modulates susceptibility, or
simply artifacts resulting from the recurrent bottlenecking of South East Asian parasites [29,
32]. If artemisinin resistance is selected in a soft sweep, the vast reservoir of variation in natural
P. falciparum populations represents a significant risk of emergent resistance disseminating
rapidly. This advocates broader molecular surveillance of Pfkelch13, and other relevant mark-
ers as they emerge [33]. Screening infected travelers returning from malaria endemic regions
Imported artemsinin resistant P. falciparum
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represents an opportunity to participate in defining changing genotypes for regions outside
South East Asia.
Epidemiologically important data such as chemoprophylaxis use is important to consider,
as this may confound the parasite population captured by surveillance. Speculation here is lim-
ited, as in many cases use or compliance to prophylaxis was not recorded, as shown in Table A
in S1 File. The patient interview format means information such as prophylaxis use is self-
reported. A significant limitation is that relevant patient information (including specific loca-
tion/s visited, previous exposure to malaria) is typically not recorded, with 81% of samples
including no additional data outside age, sex, and origin (Table A in S1 File). This could be
overcome to some degree by implementing a rudimentary questionnaire for imported malaria
cases. This would collect valuable clinical data to enrich genotyping results, while placing nom-
inal burden on healthcare workers.
Conclusions
Locally, this study identifies a risk of imported resistant falciparum malaria in Australia. As
resistance to artemisinin and partner drugs continues to increase and spread globally, this risk
will increase, and Australia needs to be prepared to respond to this. Ongoing resistance screen-
ing will improve case management and contribute to global data gathering efforts.
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